- Question
- Does transcatheter tricuspid edge-to-edge repair (TEER) improve clinical outcomes and quality of life in patients with symptomatic severe tricuspid regurgitation compared with medical therapy alone?
- Design
- Prospective randomized 1:1 trial of 350 patients enrolled at 65 centers in the United States, Canada, and Europe. The registry lists single-blind masking, and the trial was sponsored by Abbott.
- Population
- Patients with symptomatic severe tricuspid regurgitation; mean age was 78 years and 54.9% were women.
- Intervention
- Percutaneous tricuspid edge-to-edge repair (TriClip device) plus medical therapy at the physician's discretion.
- Control
- Medical therapy alone (control group), at the physician's discretion.
- Primary outcome
- Hierarchical composite of death from any cause or tricuspid-valve surgery, hospitalization for heart failure, and improvement in quality of life (an increase of at least 15 KCCQ points at 1 year).
- Results
- The primary end point favored TEER (win ratio, 1.48; 95% CI, 1.06 to 2.13; P = 0.02). The incidence of death or tricuspid-valve surgery and the rate of heart failure hospitalization did not appear to differ between groups. KCCQ changed by a mean of 12.3 ± 1.8 points with TEER versus 0.6 ± 1.8 points in controls (P < 0.001). At 30 days, 87.0% of the TEER group and 4.8% of controls had tricuspid regurgitation no greater than moderate (P < 0.001).
- Safety
- The procedure was safe: 98.3% of patients who underwent TEER were free from major adverse events at 30 days.
- Conclusion
- Tricuspid TEER was safe, reduced the severity of tricuspid regurgitation, and was associated with improved quality of life, without clear differences in death, surgery, or heart failure hospitalization.
- Why it matters
- It provided the first randomized evidence that a transcatheter therapy for tricuspid regurgitation improves how patients feel and function, opening an option for those at high surgical risk with few alternatives.
Card generated automatically with AI from the abstract of the original publication and the trial registry; every figure was checked against those sources. It may contain errors: verify the data at the source before using it for clinical decisions.
Generated on October 7, 2026